[go: up one dir, main page]

MX2019006207A - Forma polimorfica de sepiapterina. - Google Patents

Forma polimorfica de sepiapterina.

Info

Publication number
MX2019006207A
MX2019006207A MX2019006207A MX2019006207A MX2019006207A MX 2019006207 A MX2019006207 A MX 2019006207A MX 2019006207 A MX2019006207 A MX 2019006207A MX 2019006207 A MX2019006207 A MX 2019006207A MX 2019006207 A MX2019006207 A MX 2019006207A
Authority
MX
Mexico
Prior art keywords
crystalline form
sepiapterin
polymorphic form
dysfunction
patient
Prior art date
Application number
MX2019006207A
Other languages
English (en)
Other versions
MX391156B (es
Inventor
E Levy Daniel
Yoshino Hiroshi
Komoda Taichi
Matsumoto Takayoshi
Kishimoto Kaito
MURATA Shunichi
Shiro Yuichi
Original Assignee
Censa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Censa Pharmaceuticals Inc filed Critical Censa Pharmaceuticals Inc
Publication of MX2019006207A publication Critical patent/MX2019006207A/es
Publication of MX391156B publication Critical patent/MX391156B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe una forma cristalina de sepiapterina, un método para preparar la forma cristalina, composiciones farmacéuticas que contienen la forma cristalina y un método para someter a tratamiento a pacientes con una enfermedad asociada con bajos niveles intracelulares de BH4 o con una disfunción de diversas vías metabólicas dependientes del BH4, que implica administrarle al paciente una cantidad eficaz de la forma cristalina.
MX2019006207A 2016-11-29 2017-11-28 Forma polimorfica de sepiapterina. MX391156B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427686P 2016-11-29 2016-11-29
PCT/US2017/063515 WO2018102314A1 (en) 2016-11-29 2017-11-28 Polymorphic form of sepiapterin

Publications (2)

Publication Number Publication Date
MX2019006207A true MX2019006207A (es) 2019-11-18
MX391156B MX391156B (es) 2025-03-21

Family

ID=62241955

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006207A MX391156B (es) 2016-11-29 2017-11-28 Forma polimorfica de sepiapterina.

Country Status (8)

Country Link
US (2) US11130760B2 (es)
EP (1) EP3548487A4 (es)
JP (1) JP7148532B2 (es)
CN (1) CN110312721A (es)
CA (1) CA3043499A1 (es)
MA (1) MA46972A (es)
MX (1) MX391156B (es)
WO (1) WO2018102314A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011132435A1 (ja) 2010-04-22 2011-10-27 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
CA3043499A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
WO2019046849A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF
ES2986920T3 (es) 2018-05-30 2024-11-13 Ptc Therapeutics Mp Inc Administración de sepiapterina sin alimentos para su uso en un método para aumentar la exposición plasmática a sepiapterina
MX2020012978A (es) * 2018-05-30 2021-04-28 Ptc Therapeutics Mp Inc Sales de sepiapterina farmacéuticamente aceptables.
EP3801534A4 (en) 2018-05-30 2022-03-16 PTC Therapeutics MP, Inc. COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE
RS66096B1 (sr) 2019-08-05 2024-11-29 Univ Virginia Commonwealth Upotreba sepiapterina i njegovih metabolita za tretiranje izlaganja zračenju
CN114650825A (zh) 2019-09-25 2022-06-21 Ptc医疗Mp公司 治疗高苯丙氨酸血症的方法
US20230110351A1 (en) 2020-01-24 2023-04-13 Ptc Therapeutics Mp, Inc. Methods for treating parkinson's disease with sepiapterin
WO2022173823A1 (en) 2021-02-09 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
EP4291190A1 (en) 2021-02-09 2023-12-20 PTC Therapeutics MP, Inc. Methods for treating glioblastomas with sepiapterin
MX2024003909A (es) * 2021-09-29 2024-06-28 Ptc Therapeutics Inc Composicion farmaceutica de sepiapterina.
CN117117299B (zh) * 2023-08-14 2024-12-06 国联汽车动力电池研究院有限责任公司 一种无机硫化物固体电解质及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
WO1996003989A1 (en) 1994-08-05 1996-02-15 Suntory Limited Remedy for spinocerebellar degeneration
CA2228970A1 (en) 1995-08-18 1997-02-27 Donald W. Landry Detection of organic compounds through regulation of antibody-catalyzed reactions
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
MXPA06004687A (es) 2003-10-31 2006-06-27 Altana Pharma Ag Uso de bh4 para el tratamiento de enfermedades respiratorias.
AU2004311544A1 (en) 2003-11-17 2005-07-21 Merck & Cie Crystalline forms of (6R) -L-erythro-tetrahydrobiopterin dihydrochloride
PT3138566T (pt) 2003-11-17 2022-02-02 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
AU2004290692A1 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
EP2436379A1 (en) 2004-11-17 2012-04-04 BioMarin Pharmaceutical Inc. Stable tablet formulation
US20100130500A1 (en) 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
PT1877370E (pt) 2005-04-28 2009-06-02 Asubio Pharma Co Ltd Método para produzir derivados hidrazona
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
JP2010523708A (ja) 2007-04-11 2010-07-15 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンを投与する方法、関連する組成物および測定方法
EA017064B1 (ru) 2008-03-10 2012-09-28 Такеда Фармасьютикал Компани Лимитед Кристаллическое производное бензимидазола
JP2011530540A (ja) 2008-08-12 2011-12-22 オルファ スイス ゲーエムベーハー テトラヒドロビオプテリンを含有する医薬剤形
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
WO2011132435A1 (ja) 2010-04-22 2011-10-27 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
US9884909B2 (en) * 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
KR20140021585A (ko) 2011-03-01 2014-02-20 루비콘 리서치 피브이티. 엘티디. 테트라하이드로바이옵테린의 안정한 조성물
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
JP6084967B2 (ja) * 2012-05-07 2017-02-22 白鳥製薬株式会社 セピアプテリン及びテトラヒドロラクトイルプテリンの製造法
WO2017218421A1 (en) 2016-06-13 2017-12-21 Meharry Medical College Modulation of the nitric oxide synthase pathway for oral health
JP2019527242A (ja) 2016-07-29 2019-09-26 ディファーマ エッセ．ア． サプロプテリンジヒドロクロリドを含む医薬組成物キット
CA3043499A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
TWI765936B (zh) 2016-11-29 2022-06-01 美商東京威力科創Ｆｓｉ股份有限公司 用以對處理腔室中之微電子基板進行處理的平移與旋轉夾頭
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2019046849A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF
ES2986920T3 (es) 2018-05-30 2024-11-13 Ptc Therapeutics Mp Inc Administración de sepiapterina sin alimentos para su uso en un método para aumentar la exposición plasmática a sepiapterina
MX2020012978A (es) 2018-05-30 2021-04-28 Ptc Therapeutics Mp Inc Sales de sepiapterina farmacéuticamente aceptables.
EP3801534A4 (en) 2018-05-30 2022-03-16 PTC Therapeutics MP, Inc. COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE
RS66096B1 (sr) 2019-08-05 2024-11-29 Univ Virginia Commonwealth Upotreba sepiapterina i njegovih metabolita za tretiranje izlaganja zračenju
CN114650825A (zh) 2019-09-25 2022-06-21 Ptc医疗Mp公司 治疗高苯丙氨酸血症的方法

Also Published As

Publication number Publication date
US20220081443A1 (en) 2022-03-17
CA3043499A1 (en) 2018-06-07
WO2018102314A1 (en) 2018-06-07
US20200010469A1 (en) 2020-01-09
MX391156B (es) 2025-03-21
EP3548487A4 (en) 2020-04-29
US12325706B2 (en) 2025-06-10
CN110312721A (zh) 2019-10-08
JP2020500931A (ja) 2020-01-16
MA46972A (fr) 2019-10-09
US11130760B2 (en) 2021-09-28
EP3548487A1 (en) 2019-10-09
JP7148532B2 (ja) 2022-10-05

Similar Documents

Publication Publication Date Title
MX2019006207A (es) Forma polimorfica de sepiapterina.
ZA202500997B (en) Benzoxazepin oxazolidinone compounds and methods of use
EA201790693A1 (ru) Коррекция фигуры
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2021013118A (es) Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton.
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
MX2018007844A (es) Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo.
NZ757929A (en) Benzoazepine analogs as inhibiting agents for bruton’s tyrosine kinase
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2020001875A (es) Forma polimorfica de tg02.
MX2022007315A (es) Formulaciones de olanzapina de liberacion sostenida.
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
PH12017501134A1 (en) Fumagillol derivatives
Fernandez-Miranda Metabolic syndrome and sedation: 2 case reports
PH12019502792A1 (en) Tetrahydropyridopyrazine modulators of gpr6
NZ798969A (en) Benzoazepine analogs as inhibiting agents for bruton’s tyrosine kinase
UA89069U (uk) Спосіб корекції активності ферментів крові індиків за протозойних інвазій
UA96488U (uk) Спосіб лікування порушень гемоваскулярного гемостазу у хворих на ішемічну хворобу серця
IN2014DE00822A (es)
UA91081U (uk) Спосіб моделювання катаракти